Alios Biopharma Says Compounds Result in Potent Antiviral Activity; Sees Clinical Trial in 2013

Alios BioPharma, Inc. today announced the discovery of first-in-class anti-RSV nucleoside analogs that will be developed for the treatment of acute RSV infection. Data from the company's discovery and preclinical studies were presented at the 8th Annual Respiratory Syncytial Virus Symposium held in Santa Fe, New Mexico from September 27-30. The company said the compounds were discovered by screening